ACT‐ONE ‐ ACTION at last on cancer cachexia by adapting a novel action beta‐blocker

Novel action beta‐blockers combine many different pharmacological effects. The espindolol exhibits effects through β and central 5‐HT1α receptors to demonstrate pro‐anabolic, anti‐catabolic, and appetite‐stimulating actions. In the ACT‐ONE trial, espindolol reversed weight loss and improved handgrip...

Descripción completa

Detalles Bibliográficos
Autores principales: Lainscak, Mitja, Laviano, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Editorials
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5011815/
https://www.ncbi.nlm.nih.gov/pubmed/27625919
http://dx.doi.org/10.1002/jcsm.12136
_version_ 1782451899354578944
author Lainscak, Mitja
Laviano, Alessandro
author_facet Lainscak, Mitja
Laviano, Alessandro
author_sort Lainscak, Mitja
collection PubMed
description Novel action beta‐blockers combine many different pharmacological effects. The espindolol exhibits effects through β and central 5‐HT1α receptors to demonstrate pro‐anabolic, anti‐catabolic, and appetite‐stimulating actions. In the ACT‐ONE trial, espindolol reversed weight loss and improved handgrip strength in patients with cachexia due to non‐small cell lung cancer or colorectal cancer. With this trial, another frontier of cachexia management is in sight. Nonetheless, more efficacy and safety data is needed before new therapeutic indications for novel action beta‐blockers can be endorsed.
format Online
Article
Text
id pubmed-5011815
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-50118152016-09-13 ACT‐ONE ‐ ACTION at last on cancer cachexia by adapting a novel action beta‐blocker Lainscak, Mitja Laviano, Alessandro J Cachexia Sarcopenia Muscle Editorials Novel action beta‐blockers combine many different pharmacological effects. The espindolol exhibits effects through β and central 5‐HT1α receptors to demonstrate pro‐anabolic, anti‐catabolic, and appetite‐stimulating actions. In the ACT‐ONE trial, espindolol reversed weight loss and improved handgrip strength in patients with cachexia due to non‐small cell lung cancer or colorectal cancer. With this trial, another frontier of cachexia management is in sight. Nonetheless, more efficacy and safety data is needed before new therapeutic indications for novel action beta‐blockers can be endorsed. John Wiley and Sons Inc. 2016-08-05 2016-09 /pmc/articles/PMC5011815/ /pubmed/27625919 http://dx.doi.org/10.1002/jcsm.12136 Text en © 2016 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of the Society of Sarcopenia, Cachexia and Wasting Disorders This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Editorials
Lainscak, Mitja
Laviano, Alessandro
ACT‐ONE ‐ ACTION at last on cancer cachexia by adapting a novel action beta‐blocker
title ACT‐ONE ‐ ACTION at last on cancer cachexia by adapting a novel action beta‐blocker
title_full ACT‐ONE ‐ ACTION at last on cancer cachexia by adapting a novel action beta‐blocker
title_fullStr ACT‐ONE ‐ ACTION at last on cancer cachexia by adapting a novel action beta‐blocker
title_full_unstemmed ACT‐ONE ‐ ACTION at last on cancer cachexia by adapting a novel action beta‐blocker
title_short ACT‐ONE ‐ ACTION at last on cancer cachexia by adapting a novel action beta‐blocker
title_sort act‐one ‐ action at last on cancer cachexia by adapting a novel action beta‐blocker
topic Editorials
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5011815/
https://www.ncbi.nlm.nih.gov/pubmed/27625919
http://dx.doi.org/10.1002/jcsm.12136
work_keys_str_mv AT lainscakmitja actoneactionatlastoncancercachexiabyadaptinganovelactionbetablocker
AT lavianoalessandro actoneactionatlastoncancercachexiabyadaptinganovelactionbetablocker

Ejemplares similares